多中心型Castleman病的治疗进展(6)

4结语

多中心型Castleman病是一种缺乏标准治疗的，有较高死亡率的罕见疾病。迄今为止，获得FDA批准用于治疗该病的药物仅有司妥昔单抗，但该药价格昂贵且目前在国内尚未上市。对中国的临床医师来说，等待该药在中国上市可能需要一定的时间，而如何在前述诸多已被证实对MCD有疗效的药物中筛选出经济、有效和安全的治疗组合，可能是短期内能够帮助中国MCD患者的较为实际的解决方案。

参考文献

[1]Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956, 9(4):822-30.

[2] Zhang L, Li Z, Cao X, et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman’s disease: renal function is an important prognostic factor.Sci Rep.2016, 6:. doi: 10.1038.

[3]Dispenzieri A,Armitage JO,Loe MJ, et al. The clinical spectrum of Castleman's disease.Am J Hematol.2012，87(11):997-1002.

[4]Fajgenbaum DC,van Rhee F,Nabel CS.HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.Blood.2014, 123(19):2924-33.

[5]Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012, 255(4):677-84.

[6] van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014,15(9):966-74.

[7]Dong Y,Wang M,Nong L,et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor.Br J Haematol.2015, 169(6):834-42.

[8] Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106(8):2627-32.

[9] Leger-Ravet MB, Peuchmaur M, Devergne O, et al. Interleukin-6 gene expression in Castleman's disease. Blood. 1991,78(11):2923.

[10] Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995, 86(4):1276-80.

[11]张路,曹欣欣,王书杰,等.Castleman病合并系统性红斑狼疮的临床特征分析[J].中国医学科学院学报,2016, 38(5):543-547.

[12]张路,李剑.Castleman病发病机制研究进展[J].中国医学科学院学报,2016, 38(1):69-72.

[13]张路,李剑,冯俊,等.TAFRO综合征一例报告.中国医学科学院学报,2016, 38(4):484-6.

[14]Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000, 96(6):2069-73.

[15]Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998, 128(8):657-62.

[16]Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985, 3(9):1202-16.

[17]Weisenburger DD, Nathwani BN, et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985, 16(2):162-72.

文章来源：《国际药学研究杂志》 网址: http://www.gjyxyjzz.cn/zonghexinwen/2020/1010/352.html